O’Brien horses withdrawn from Arc following positive samples

Mogul is one of four Aidan O'Brien horses who will miss the Prix de l'Arc de Triomphe
Mogul is one of four Aidan O'Brien horses who will miss the Prix de l'Arc de Triomphe - (Copyright PA Wire)
22:22pm, Sat 03 Oct 2020
CBAD8A00-D2B9-4E0E-ADDF-D0366C357A34 Created with sketchtool. E9A4AA46-7DC3-48B8-9CE2-D75274FB8967 Created with sketchtool. 65CCAE04-4748-4D0F-8696-A91D8EB3E7DC Created with sketchtool.

Aidan O’Brien’s four planned runners in the Qatar Prix de l’Arc de Triomphe have all been withdrawn from the race after positive urine samples indicated the presence of a banned substance from contaminated feed.

O’Brien was due to field Japan, Sovereign, Mogul and Serpentine against Enable at ParisLongchamp on Sunday, as John Gosden’s mare bids to win the great race for an unprecedented third time.

None of the quartet will, however, take part after it emerged late on Saturday evening that they have tested positive for a banned substance, believed to be zilpaterol – potentially from batches of feed supplied by Gain Equine Nutrition.

On Friday, the supplier confirmed that it is “investigating the potential presence of a contaminant in some batches of our equine feed range”.

The absence of O’Brien’s runners was announced via a Tweet on the official account of O’Brien’s Ballydoyle yard.

It read: “Unfortunately the results of the urine samples taken from the horses yesterday have come back positive from the French laboratory.

“There is a possibility that the contaminant may have left their system by the time of racing tomorrow – however we have no guarantee of this, and in order to protect the integrity of racing we have decided to withdraw all our horses from racing tomorrow.

“Joseph and Donnacha O’Brien will do likewise.”

O’Brien’s two sons each had leading Group One contenders due to race on Sunday.

Donnacha’s Fancy Blue was declared in the Prix de l’Opera, while his older brother Joseph had Pretty Gorgeous in the Qatar Prix Marcel Boussac.

Sign up to our newsletter